Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Florida Weight Loss MD vs NuuVim

Florida Weight Loss MD
Graded #329

Lower grade

vs+8.100000000000001
NuuVim
Graded #153

Higher grade

The verdict

NuuVim takes it — 68.2/100 to 60.1/100.

NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuuVim +37
51
88
Dose & formulationNuuVim +43
53
96
Clinical oversightFlorida Weight Loss MD +36
78
42
Labs & monitoringFlorida Weight Loss MD +12
62
50
FulfillmentFlorida Weight Loss MD +6
67
61
Contract termsEven
47
47
Florida Weight Loss MD · left barNuuVim · right bar

The numbers

MetricFlorida Weight Loss MDNuuVim
WeighScore60.1/10068.2/100
GradeCC
Scorecard rank#329#153
SemaglutideNot disclosed$79/mo (all doses, 3-mo plan, new patients only, compounded)
TirzepatideNot disclosed$133/mo (all doses, 3-mo plan, new patients only, compounded)
Coverage1 stateCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
Florida Weight Loss MD

Graded #329 · C

Strengths

  • Physician-led (Dr. Sergey Terushkin, MD, FACS) with same-day telehealth visits statewide in Florida
  • Offers both compounded GLP-1 and brand Wegovy/Ozempic/Mounjaro/Zepbound when appropriate
  • Accepts most insurance or self-pay; consult $99 with $49 applied to the program

Where it loses points

  • Florida residents only — no service outside the state
  • Monthly medication pricing is not published; disclosed after evaluation
  • Single-clinic operation rather than a national telehealth platform
NuuVim

Graded #153 · C

Strengths

  • Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
  • Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
  • LegitScript Certified and HIPAA-compliant
  • Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
  • Operating legal entity disclosed: NuuVim LLC, Texas governing law

Where it loses points

  • There is no month-to-month plan: every rate is billed as one three-month payment
  • The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
  • The site's own llms.txt advertises pricing, FAQ and terms files that all 404
  • No state count is published
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard